Dysregulation of alternative splicing contributes to multiple myeloma pathogenesis.

ABSTRACT:

Background

Dysregulation of alternative splicing (AS) triggers many tumours, understanding the roles of splicing events during tumorigenesis would open new avenues for therapies and prognosis in multiple myeloma (MM).

Methods

Molecular, genetic, bioinformatic and statistic approaches are used to determine the mechanism of the candidate splicing factor (SF) in myeloma cell lines, myeloma xenograft models and MM patient samples.

Results

GSEA reveals a significant difference in the expression pattern of the alternative splicing pathway genes, notably enriched in MM patients. Upregulation of the splicing factor SRSF1 is observed in the progression of plasma cell dyscrasias and predicts MM patients' poor prognosis. The c-indices of the Cox model indicated that SRSF1 improv

SUBMITTER: Song S 

PROVIDER: S-EPMC10006196 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature